Heron Therapeutics | HRTX - Current Assets


Heron Therapeutics reported $228.98M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
ALKERMES USD 1.36B 570.52M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amarin USD 626.02M 23.87M Mar/2026
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
Eisai JPY 761.64B 79.24B Mar/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 514.96M 33.01M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Surmodics USD 75.99M 5.31M Jun/2025
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Veracyte USD 522.17M 33.8M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026